tiprankstipranks
Advertisement
Advertisement

IL:CANF Stock Latest News

Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
The FlyCan-Fite BioPharma secures Australian Patent Office allowance for namodenoson
9d ago
CANF
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
PremiumThe Fly
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
17d ago
CANF
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
PremiumThe Fly
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
21d ago
CANF
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
PremiumThe Fly
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
22d ago
CANF
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
PremiumThe Fly
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
27d ago
CANF
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
PremiumThe FlyCan-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
2M ago
CANF
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
Premium
The Fly
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
2M ago
CANF
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
Premium
The Fly
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
4M ago
CANF
Can-Fite BioPharma completes enrollment in Piclidenoson study
PremiumThe Fly
Can-Fite BioPharma completes enrollment in Piclidenoson study
4M ago
CANF
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
PremiumThe Fly
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
4M ago
CANF
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
PremiumThe Fly
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
5M ago
CANF
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
PremiumThe Fly
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
5M ago
CANF
Can-Fite BioPharma receives Canadian patent allowance for namodenoson
PremiumThe FlyCan-Fite BioPharma receives Canadian patent allowance for namodenoson
5M ago
CANF
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
Premium
The Fly
Can-Fite announces patient with liver cirrhosis treated with Namodenoson
6M ago
CANF
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
Premium
The Fly
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
6M ago
CANF
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
PremiumThe Fly
Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital
7M ago
CANF
Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
PremiumThe Fly
Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
7M ago
CANF
Can-Fite BioPharma provides clinical, financial update
PremiumThe Fly
Can-Fite BioPharma provides clinical, financial update
7M ago
CANF
Can-Fite BioPharma to participate in BioFIT 2025
PremiumThe Fly
Can-Fite BioPharma to participate in BioFIT 2025
8M ago
CANF
Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602
PremiumThe FlyCan-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602
8M ago
CANF
Can-Fite announces 9-year survival with complete cure with Namodenoson
Premium
The Fly
Can-Fite announces 9-year survival with complete cure with Namodenoson
8M ago
CANF
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
Premium
Ratings
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
9M ago
CANF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >